BACKGROUND: Vitamin D compounds inhibit prostate tumorigenesis experimentally, but epidemiologic data are inconsistent with respect to prostate cancer risk, with some studies suggesting nonsignificant positive associations. METHODS: The 25-hydroxy vitamin D [25(OH)D]-prostate cancer relation was examined in a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of 50- to 69-year-old Finnish men. We matched 1,000 controls to 1,000 cases diagnosed during up to 20 years of follow-up on the basis of age (±1 year) and fasting blood collection date (±30 days). Conditional multivariate logistic regression models estimated ORs and 95% CIs. All statistical significance testing was 2-sided. RESULTS: Cases had nonsignificantly 3% higher serum 25(OH)D levels (P = 0.19). ORs (95% CIs) for increasing season-specific quintiles of 25(OH)D concentrations were 1.00 (reference), 1.29 (0.95-1.74), 1.34 (1.00-1.80), 1.26 (0.93-1.72), and 1.56 (1.15-2.12), with P(trend) = 0.01. Analyses based on prespecified clinical categories and season-adjusted values yielded similar results. These findings seemed stronger for aggressive disease [OR (95% CI) for fifth quintile of serum 25(OH)D [1.70 (1.05-2.76), P(trend) = 0.02], among men with greater physical activity [1.85 (1.26-2.72), P(trend) = 0.002], higher concentrations of serum total cholesterol [2.09 (1.36-3.21), P(trend) = 0.003] or α-tocopherol [2.00 (1.30-3.07), P(trend) = 0.01] and higher intakes of total calcium [1.82 (1.20-2.76), P(trend) = 0.01] or vitamin D [1.69 (1.04-2.75), P(trend) = 0.08], or among those who had received the trial α-tocopherol supplements [1.74 (1.15-2.64), P(trend) = 0.006]. CONCLUSION: Our findings indicate that men with higher vitamin D blood levels are at increased risk of developing prostate cancer. IMPACT: Greater caution is warranted with respect to recommendations for high-dose vitamin D supplementation and higher population target blood levels.
BACKGROUND:Vitamin D compounds inhibit prostate tumorigenesis experimentally, but epidemiologic data are inconsistent with respect to prostate cancer risk, with some studies suggesting nonsignificant positive associations. METHODS: The 25-hydroxy vitamin D [25(OH)D]-prostate cancer relation was examined in a nested case-control study within the Alpha-Tocopherol, Beta-CaroteneCancer Prevention Study of 50- to 69-year-old Finnish men. We matched 1,000 controls to 1,000 cases diagnosed during up to 20 years of follow-up on the basis of age (±1 year) and fasting blood collection date (±30 days). Conditional multivariate logistic regression models estimated ORs and 95% CIs. All statistical significance testing was 2-sided. RESULTS: Cases had nonsignificantly 3% higher serum 25(OH)D levels (P = 0.19). ORs (95% CIs) for increasing season-specific quintiles of 25(OH)D concentrations were 1.00 (reference), 1.29 (0.95-1.74), 1.34 (1.00-1.80), 1.26 (0.93-1.72), and 1.56 (1.15-2.12), with P(trend) = 0.01. Analyses based on prespecified clinical categories and season-adjusted values yielded similar results. These findings seemed stronger for aggressive disease [OR (95% CI) for fifth quintile of serum 25(OH)D [1.70 (1.05-2.76), P(trend) = 0.02], among men with greater physical activity [1.85 (1.26-2.72), P(trend) = 0.002], higher concentrations of serum total cholesterol [2.09 (1.36-3.21), P(trend) = 0.003] or α-tocopherol [2.00 (1.30-3.07), P(trend) = 0.01] and higher intakes of total calcium [1.82 (1.20-2.76), P(trend) = 0.01] or vitamin D [1.69 (1.04-2.75), P(trend) = 0.08], or among those who had received the trial α-tocopherol supplements [1.74 (1.15-2.64), P(trend) = 0.006]. CONCLUSION: Our findings indicate that men with higher vitamin D blood levels are at increased risk of developing prostate cancer. IMPACT: Greater caution is warranted with respect to recommendations for high-dose vitamin D supplementation and higher population target blood levels.
Authors: A M Nomura; G N Stemmermann; J Lee; L N Kolonel; T C Chen; A Turner; M F Holick Journal: Cancer Causes Control Date: 1998-08 Impact factor: 2.506
Authors: P Pietinen; A M Hartman; E Haapa; L Räsänen; J Haapakoski; J Palmgren; D Albanes; J Virtamo; J K Huttunen Journal: Am J Epidemiol Date: 1988-09 Impact factor: 4.897
Authors: O P Heinonen; D Albanes; J Virtamo; P R Taylor; J K Huttunen; A M Hartman; J Haapakoski; N Malila; M Rautalahti; S Ripatti; H Mäenpää; L Teerenhovi; L Koss; M Virolainen; B K Edwards Journal: J Natl Cancer Inst Date: 1998-03-18 Impact factor: 13.506
Authors: Elizabeth A Platz; Michael F Leitzmann; Bruce W Hollis; Walter C Willett; Edward Giovannucci Journal: Cancer Causes Control Date: 2004-04 Impact factor: 2.506
Authors: Elizabeth T Jacobs; Anna R Giuliano; María Elena Martínez; Bruce W Hollis; Mary E Reid; James R Marshall Journal: J Steroid Biochem Mol Biol Date: 2004-05 Impact factor: 4.292
Authors: Pentti Tuohimaa; Leena Tenkanen; Merja Ahonen; Sonja Lumme; Egil Jellum; Göran Hallmans; Pär Stattin; Sverre Harvei; Timo Hakulinen; Tapio Luostarinen; Joakim Dillner; Matti Lehtinen; Matti Hakama Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: María Elena Martínez; Elizabeth T Jacobs; John A Baron; James R Marshall; Tim Byers Journal: J Natl Cancer Inst Date: 2012-04-25 Impact factor: 13.506
Authors: Shih-Wen Lin; David C Wheeler; Yikyung Park; Elizabeth K Cahoon; Albert R Hollenbeck; D Michal Freedman; Christian C Abnet Journal: Int J Cancer Date: 2012-05-29 Impact factor: 7.396
Authors: C J Paller; Y M Kanaan; D A Beyene; T J Naab; R L Copeland; H L Tsai; N F Kanarek; T S Hudson Journal: Prostate Date: 2015-06-05 Impact factor: 4.104
Authors: Stephanie J Weinstein; Alison M Mondul; Kai Yu; Tracy M Layne; Christian C Abnet; Neal D Freedman; Racheal Z Stolzenberg-Solomon; Unhee Lim; Mitchell H Gail; Demetrius Albanes Journal: Eur J Epidemiol Date: 2018-08-02 Impact factor: 8.082
Authors: Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey Journal: J Oncol Pharm Pract Date: 2014-07-01 Impact factor: 1.809
Authors: Alison M Mondul; Stephanie J Weinstein; Kristin A Moy; Satu Männistö; Demetrius Albanes Journal: Int J Cancer Date: 2014-01-30 Impact factor: 7.396
Authors: Shakira M Nelson; Orestis A Panagiotou; Gabriella M Anic; Alison M Mondul; Satu Männistö; Stephanie J Weinstein; Demetrius Albanes Journal: Int J Epidemiol Date: 2016-08-14 Impact factor: 7.196